2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.95 (Poster) STK11, KEAP1, and KRAS mutation epidemiology and real-world outcomes in US patients with newly diagnosed metastatic non-small cell lung cancer

PP01.95 (Poster) STK11, KEAP1, and KRAS mutation epidemiology and real-world outcomes in US patients with newly diagnosed metastatic non-small cell lung cancer

Back to course

Pdf Summary

This study aimed to assess the prevalence of mutations and co-mutations of STK11, KEAP1, and KRAS in metastatic non-small cell lung cancer (mNSCLC) patients and to describe treatment patterns and clinical outcomes in these patients. The study found that STK11, KEAP1, and KRAS mutations and co-mutations are common in mNSCLC patients. Patients with these mutations and co-mutations had poor outcomes with current treatments. The study suggests that novel treatment options and further clinical trials should be considered for these patient subgroups.<br /><br />The study included 964 newly diagnosed mNSCLC patients. The prevalence of STK11, KEAP1, and KRAS mutations were 18.2%, 14.6%, and 35.2% respectively. These mutations were more common in non-squamous mNSCLC patients. The majority of patients had PD-L1 negative status.<br /><br />The most frequently used first-line treatments were immuno-oncology (IO)-chemotherapy combinations, platinum-based chemotherapy, and IO monotherapy. Despite the association of these mutations with PD-L1 inhibitor resistance, a significant proportion of patients with these mutations received IO therapies.<br /><br />The median real-world progression-free survival (rwPFS) from diagnosis was 5.7 months and the median real-world overall survival (rwOS) was 10.1 months. Patients with STK11, KEAP1, and KRAS mutations had reduced rwPFS and rwOS compared to those without these mutations.<br /><br />The study has some limitations, including a small sample size and the inclusion of only newly diagnosed mNSCLC patients. The study used data from the Flatiron Health-CGDB, which may not be representative of all mNSCLC patients. Missing clinical information of interest, such as comorbidities and biomarkers, could also affect the generalizability of the findings.<br /><br />In conclusion, this study provides insights into the prevalence of mutations and co-mutations in mNSCLC patients and their association with treatment patterns and clinical outcomes. The findings suggest the need for novel treatment options and further clinical trials for patients with STK11, KEAP1, and KRAS mutations.

Asset Subtitle

Daniel Simmons

Keywords

mutations

co-mutations

STK11

KEAP1

KRAS

metastatic non-small cell lung cancer

mNSCLC

treatment patterns

clinical outcomes

prevalence